Please login to the form below

Not currently logged in
Email:
Password:

Castleman

This page shows the latest Castleman news and features for those working in and with pharma, biotech and healthcare.

Roche snags pair of FDA breakthrough designations

Roche snags pair of FDA breakthrough designations

First launched in Japan for 2005 for Castleman's disease - and subsequently getting the green light for rheumatoid arthritis and systemic juvenile idiopathic arthritis in several markets including the US and

Latest news

  • Roche wins early use RA approval for RoActemra in Europe Roche wins early use RA approval for RoActemra in Europe

    Adds to existing indications in arthritis and Castleman’s disease. Roche's arthritis brand RoActemra (tocilizumab) has widened its European licence, winning a new EU indication to treat early rheumatoid arthritis.

  • EC approves Janssen rare blood disorder drug EC approves Janssen rare blood disorder drug

    Sylvant available to treat multicentric Castleman's disease. Janssen's Sylvant this week became the first drug approved in Europe to treat the rare blood disorder multicentric Castleman's disease (MCD).

  • FDA approves Janssen drug for rare Castleman’s disease FDA approves Janssen drug for rare Castleman’s disease

    Sylvant approved to treat lymphoma-like condition. The US FDA has approved a new drug to treat a rare cancer-like condition known as multicentric Castleman's disease. ... It is also designated an orphan drug due to the rarity of multicentric Castleman's

  • EMA backs Janssen rare disease drug for approval EMA backs Janssen rare disease drug for approval

    Castleman's disease treatment Sylvant wins CHMP recommendation. J&J subsidiary Janssen-Cilag's Castleman's disease treatment Sylvant (situximab) has been recommended for approval in Europe. ... Castleman's disease is a rare disorder characterised by

  • J&J files rare blood disorder drug siltuximab in US and EU J&J files rare blood disorder drug siltuximab in US and EU

    Orphan drug to be assessed for use in the treatment of multicentric Castleman disease. ... multicentric Castleman disease (MCD) who do not have HIV or human herpes virus-8.

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics